Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #5 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited (this stock) | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 7,119 | 1,082 | 786 | ₹ |
| March 31, 2026 | 6,541 | 707 | 543 | ₹ |
| Dec. 31, 2025 | 7,074 | 893 | 674 | ₹ |
| Sept. 30, 2025 | 7,589 | 1,854 | 1,353 | ₹ |
| June 30, 2025 | 6,957 | 1,770 | 1,292 | ₹ |
| March 31, 2025 | 6,730 | 1,504 | 1,214 | ₹ |
| Dec. 31, 2024 | 7,073 | 1,916 | 1,575 | ₹ |
| Sept. 30, 2024 | 7,051 | 1,789 | 1,305 | ₹ |
| June 30, 2024 | 6,694 | 1,611 | 1,175 | ₹ |
| March 31, 2024 | 6,163 | 1,259 | 932 | ₹ |
| Dec. 31, 2023 | 6,604 | 1,474 | 1,068 | ₹ |
| Sept. 30, 2023 | 6,678 | 1,594 | 1,155 | ₹ |
| June 30, 2023 | 6,329 | 1,375 | 998 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 28,163 | 5,224 | 3,862 |
| March 31, 2025 | 27,548 | 6,821 | 5,269 |
| March 31, 2024 | 25,774 | 5,702 | 4,154 |
| March 31, 2023 | 22,753 | 4,038 | 2,833 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 3,940 | -2,326 | -1,234 | 1,599 | 2,341 |
| March 31, 2025 | 5,005 | -3,691 | -1,293 | 1,162 | 3,843 |
| March 31, 2024 | 4,134 | -2,988 | -1,200 | 1,098 | 3,036 |
| March 31, 2023 | 3,238 | -2,389 | -958 | 841 | 2,397 |
| March 31, 2022 | 3,326 | -1,872 | -1,600 | 544 | 2,782 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 42,496 | 34,520 | 34,270 | 140 | 117 | 24,146 | 7,014 | 1,018 | 6,040 | 6,597 |
| March 31, 2025 | 37,387 | 31,289 | 31,032 | 80 | 12 | 23,249 | 5,484 | 589 | 5,262 | 5,642 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
